137 related articles for article (PubMed ID: 17545635)
1. MUC1 oncoprotein promotes refractoriness to chemotherapy in thyroid cancer cells.
Siragusa M; Zerilli M; Iovino F; Francipane MG; Lombardo Y; Ricci-Vitiani L; Di Gesù G; Todaro M; De Maria R; Stassi G
Cancer Res; 2007 Jun; 67(11):5522-30. PubMed ID: 17545635
[TBL] [Abstract][Full Text] [Related]
2. Suppressor of cytokine signaling 3 sensitizes anaplastic thyroid cancer to standard chemotherapy.
Francipane MG; Eterno V; Spina V; Bini M; Scerrino G; Buscemi G; Gulotta G; Todaro M; Dieli F; De Maria R; Stassi G
Cancer Res; 2009 Aug; 69(15):6141-8. PubMed ID: 19638576
[TBL] [Abstract][Full Text] [Related]
3. Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells.
Todaro M; Zerilli M; Ricci-Vitiani L; Bini M; Perez Alea M; Maria Florena A; Miceli L; Condorelli G; Bonventre S; Di Gesù G; De Maria R; Stassi G
Cancer Res; 2006 Feb; 66(3):1491-9. PubMed ID: 16452205
[TBL] [Abstract][Full Text] [Related]
4. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10.
Stassi G; Todaro M; Zerilli M; Ricci-Vitiani L; Di Liberto D; Patti M; Florena A; Di Gaudio F; Di Gesù G; De Maria R
Cancer Res; 2003 Oct; 63(20):6784-90. PubMed ID: 14583474
[TBL] [Abstract][Full Text] [Related]
5. Human mucin 1 oncoprotein represses transcription of the p53 tumor suppressor gene.
Wei X; Xu H; Kufe D
Cancer Res; 2007 Feb; 67(4):1853-8. PubMed ID: 17308127
[TBL] [Abstract][Full Text] [Related]
6. Targeting RET to induce medullary thyroid cancer cell apoptosis: an antagonistic interplay between PI3K/Akt and p38MAPK/caspase-8 pathways.
Mazumdar M; Adhikary A; Chakraborty S; Mukherjee S; Manna A; Saha S; Mohanty S; Dutta A; Bhattacharjee P; Ray P; Chattopadhyay S; Banerjee S; Chakraborty J; Ray AK; Sa G; Das T
Apoptosis; 2013 May; 18(5):589-604. PubMed ID: 23329180
[TBL] [Abstract][Full Text] [Related]
7. Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma.
Milosevic Z; Pesic M; Stankovic T; Dinic J; Milovanovic Z; Stojsic J; Dzodic R; Tanic N; Bankovic J
Transl Res; 2014 Nov; 164(5):411-23. PubMed ID: 25016932
[TBL] [Abstract][Full Text] [Related]
8. IL-22-mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression in vitro.
Brand S; Dambacher J; Beigel F; Zitzmann K; Heeg MH; Weiss TS; Prüfer T; Olszak T; Steib CJ; Storr M; Göke B; Diepolder H; Bilzer M; Thasler WE; Auernhammer CJ
Am J Physiol Gastrointest Liver Physiol; 2007 Apr; 292(4):G1019-28. PubMed ID: 17204547
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways.
Puhr M; Santer FR; Neuwirt H; Susani M; Nemeth JA; Hobisch A; Kenner L; Culig Z
Cancer Res; 2009 Sep; 69(18):7375-84. PubMed ID: 19738059
[TBL] [Abstract][Full Text] [Related]
10. High glucose induces suppression of insulin signalling and apoptosis via upregulation of endogenous IL-1beta and suppressor of cytokine signalling-1 in mouse pancreatic beta cells.
Venieratos PD; Drossopoulou GI; Kapodistria KD; Tsilibary EC; Kitsiou PV
Cell Signal; 2010 May; 22(5):791-800. PubMed ID: 20067833
[TBL] [Abstract][Full Text] [Related]
11. Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells.
Lin CI; Whang EE; Abramson MA; Donner DB; Bertagnolli MM; Moore FD; Ruan DT
Biochem Biophys Res Commun; 2009 Feb; 379(2):626-31. PubMed ID: 19124005
[TBL] [Abstract][Full Text] [Related]
12. MUC1 alters oncogenic events and transcription in human breast cancer cells.
Hattrup CL; Gendler SJ
Breast Cancer Res; 2006; 8(4):R37. PubMed ID: 16846534
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-11 promotes epithelial-mesenchymal transition in anaplastic thyroid carcinoma cells through PI3K/Akt/GSK3β signaling pathway activation.
Zhong Z; Hu Z; Jiang Y; Sun R; Chen X; Chu H; Zeng M; Sun C
Oncotarget; 2016 Sep; 7(37):59652-59663. PubMed ID: 27487122
[TBL] [Abstract][Full Text] [Related]
14. Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents.
Ren J; Agata N; Chen D; Li Y; Yu WH; Huang L; Raina D; Chen W; Kharbanda S; Kufe D
Cancer Cell; 2004 Feb; 5(2):163-75. PubMed ID: 14998492
[TBL] [Abstract][Full Text] [Related]
15. Role of the MUC1-C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma.
Shigeta K; Hasegawa M; Kikuchi E; Yasumizu Y; Kosaka T; Mizuno R; Mikami S; Miyajima A; Kufe D; Oya M
Cancer Sci; 2020 Oct; 111(10):3639-3652. PubMed ID: 32677159
[TBL] [Abstract][Full Text] [Related]
16. Significance of expression of suppressor of cytokine signaling proteins: Suppressor of cytokine signaling-1, suppressor of cytokine signaling-2, and suppressor of cytokine signaling-3 in papillary thyroid cancer.
Kobawala TP; Trivedi TI; Gajjar KK; Patel GH; Ghosh NR
J Cancer Res Ther; 2017; 13(2):337-345. PubMed ID: 28643757
[TBL] [Abstract][Full Text] [Related]
17. MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90.
Ren J; Bharti A; Raina D; Chen W; Ahmad R; Kufe D
Oncogene; 2006 Jan; 25(1):20-31. PubMed ID: 16158055
[TBL] [Abstract][Full Text] [Related]
18. c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition.
Byeon HK; Na HJ; Yang YJ; Kwon HJ; Chang JW; Ban MJ; Kim WS; Shin DY; Lee EJ; Koh YW; Yoon JH; Choi EC
Mol Carcinog; 2016 Nov; 55(11):1678-1687. PubMed ID: 26456083
[TBL] [Abstract][Full Text] [Related]
19. Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein.
Jin C; Rajabi H; Rodrigo CM; Porco JA; Kufe D
Oncogene; 2013 Apr; 32(17):2179-88. PubMed ID: 22689062
[TBL] [Abstract][Full Text] [Related]
20. Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.
Byeon HK; Na HJ; Yang YJ; Ko S; Yoon SO; Ku M; Yang J; Kim JW; Ban MJ; Kim JH; Kim DH; Kim JM; Choi EC; Kim CH; Yoon JH; Koh YW
Oncotarget; 2017 Jan; 8(1):596-609. PubMed ID: 27880942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
